Aller au contenu

Safety and efficacy of nintedanib as second-line therapy for patients with differentiated or medullary thyroid cancer progressing after first-line therapy. A randomized phase II study of the EORTC Endocrine Task Force (protocol 1209-EnTF).

Nom du journal : Front Endocrinol (Lausanne)

Année : 2024

Volume : 15

Page de départ : 1403687

Auteurs: Leboulleux, S, Kapiteijn, E, Litière, S, Schöffski, P, Godbert, Y, Rodien, P & al,